Explore every episode of the podcast NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In episode 172, “Spinal Muscular Atrophy Awareness Month: Why Multidisciplinary Care Matters,” Sandeep Rana, MD, a neurologist specializing in neuromuscular disorders at Allegheny Health Network, discussed the multidisciplinary care model for spinal muscular atrophy (SMA) implemented in his center, in honor of SMA Awareness Month. He described a clinic structure that includes physical and occupational therapists, respiratory therapists, nutritionists, speech therapists, social workers, and collaboration with pulmonologists experienced in neuromuscular disease.

Rana also outlined how the advent of disease-modifying therapies has transformed SMA from a largely fatal illness into a more manageable condition. He highlighted key advancements in therapeutics that have shifted priorities toward long-term wellness, including weight management, physical fitness, and emotional health. He noted persistent challenges in organizing and sustaining a specialized multidisciplinary team. Finally, he emphasized the importance of clinician awareness, early identification, and timely referral to tertiary centers, particularly as additional therapies may become available.

Looking for more neuromuscular disorder discussions? Check out the NeurologyLive® Neuromuscular Disorders clinical focus page.

Episode Breakdown:

• 1:25 – Professional background and clinic overview
• 2:55 – What an effective multidisciplinary SMA care team looks like
• 5:12 – How disease-modifying therapies have changed SMA care
• 6:28 – Neurology News Minute 
• 9:27 – Organizational and procedural challenges in coordinating care
• 11:52 – Why raising awareness about SMA is important & advice to clinicians
• 13:45 – Key message about SMA today 

The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts SL1009 Resubmission for PDCD, Sets December PDUFA Date
• FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy
• FDA Grants RMAT Designation to Sasineprocel for Parkinson Disease

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special edition of Mind Moments, Na Tosha Gatson, MD, PhD, senior medical director of neuro-oncology and director of the Center for Neuro-Oncology at Indiana University School of Medicine, joins the podcast to discuss her career journey, philosophy of patient care, and the launch of The G.L.O.B., a new recurring NeurologyLive column dedicated to advancing health literacy in neuro-oncology. Drawing on decades of experience in neuro-oncology, clinical leadership, and mentorship, Gatson shares the motivation behind creating a platform that transforms complex oncologic concepts into practical, accessible knowledge for clinicians, patients, and caregivers alike. 

The conversation explores the inspiration behind The G.L.O.B., the importance of effective medical communication, lessons learned throughout Gatson's career, and the role of health literacy, shared decision-making, and health equity in modern neurologic care. She also discusses her vision for the future of the column and why improving patient understanding should remain central to both clinical practice and research. 

Episode Breakdown:

• 1:10 – Journey into neuro-oncology and career-defining experiences
• 4:50 – Mission and philosophy behind The G.L.O.B.
• 7:10 – Key themes readers can expect from the column
• 9:45 – Career lessons that shaped Dr. Gatson's clinical practice
• 16:30 – Vision for The G.L.O.B. and improving healthy literacy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Sarah Hoffmann, MD, PhD, senior neurologist at Charité – University Medicine Berlin, provides clinical insight into the evolving and often challenging landscape of seronegative generalized myasthenia gravis (gMG). Drawing from both clinical experience and research, Hoffmann discusses how seronegative MG is defined in the absence of detectable antibodies and why it represents a heterogeneous and often underrecognized subgroup of patients. The conversation explores key diagnostic challenges, particularly in patients with limb-predominant symptoms, where differentiation from other neuromuscular or functional disorders can be difficult. Hoffmann also reviews current treatment approaches, noting that while standard therapies mirror antibody-positive MG, access to targeted treatments remains limited. Additional discussion focuses on the barriers to advancing clinical trials in this population, the need for reliable biomarkers to better stratify patients, and the importance of continually reassessing diagnosis in nonresponders to avoid both undertreatment and overtreatment.

Looking for more neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:15 – Defining seronegative MG and estimating prevalence within overall patient population 
• 2:15 – Diagnostic challenges and distinguishing seronegative MG from mimics and functional disorders 
• 5:35 – Role and limitations of antibody testing, electrophysiology, and pharmacologic response 
• 6:50 – Neurology News Network 
• 9:05 – Current treatment strategies and variability in access to targeted therapies 
• 11:55 – Barriers to clinical trials and need for improved patient stratification methods 
• 13:05 – Key unanswered questions including biomarkers and reassessing diagnosis in nonresponders 

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Zilganersen New Drug Application for Priority Review in Alexander Disease
• FDA Grants Accelerated Approval to Tividenofusp Alfa for Neurologic Hunter Syndrome
• FDA Approves Higher Strength, More Effective Nusinersen Dose for Spinal Muscular Atrophy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of tofersen (Qalsody; Biogen/Ionis) in SOD1 mutation-mediated amyotrophic lateral sclerosis (ALS). Offering commentary is Angela Genge, MD, FRCPC, the director of the ALS Centre of Excellence for Research and Patient Care at McGill University, and an executive at the Clinical Research Unit at The Neuro (Montreal Neurological Institute-Hospital). Tofersen is an antisense oligonucleotide, and its new drug application (NDA) was supported by data from a phase 1 study of healthy volunteers, a phase 1/2 dose-ascending study, the pivotal phase 3 VALOR study (NCT02623699), and its open-label extension.

For more of NeurologyLive®'s coverage of tofersen's approval, head here: FDA Approves Tofersen as First SOD1-ALS Treatment
Episode Breakdown:

• 0:30 – Tofersen (Qalsody; Biogen/Ionis) approved for SOD1-ALS
• 1:35 – Angela Genge, MD, FRCPC, on the approval
• 3:05 – The implications of targeting a root cause of ALS
• 5:00 – Data from the supporting VALOR study
• 5:55 – Genge on the context around the trial data
• 7:35 – Questions about access to tofersen amid accelerated approval

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. News release. FDA. April 25, 2023. Accessed April 25, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene
2. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099-1110. doi:10.1056/NEJMoa2204705.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Robert Zivadinov, MD, PhD, director of the Buffalo Neuroimaging Analysis Center, and a professor of neurology and biomedical informatics at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo. He discussed the recent CASA-MS study that he and colleagues conducted into a subgroup of patients with multiple sclerosis (MS) who develop rapid and progressive disability at a relatively young age, which he presented earlier this year at the 2023 Americas Committee for Treatment and Research in MS Forum, and the critical effectively need to treat this group of patients. The study was carried out at The Boston Home, a specialized residential facility for individuals with advanced progressive neurological disorders, in Dorchester, Massachusetts, and at the University at Buffalo, in New York.

Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.

Episode Breakdown:

• 1:10 – Background on the CASA-MS study subpopulation
• 3:45 – Topline results of the study
• 6:05 – The need for further clarification in MS populations
• 7:10 – The utility of biomarkers such as GFAP
• 12:15 – Further assessment plans for the CASA-MS cohort
• 14:15 – Neurology News Minute
• 18:35 – Access to the tools to characterize progressive MS
• 21:30 – The potential with portable MRI and artificial intelligence
• 25:25 – Unmet needs in progressive MS

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Phase 3 Study of GTX-104 in Subarachnoid Hemorrhage Expected to Proceed Following FDA Feedback
• FDA Places Partial Hold on Evobrutinib Initiation in Newly Enrolled Patients With MS
• FDA Panel Votes in Favor of Brexpiprazole as Potential Therapy for Alzheimer Agitation
• FDA Approves IntelGenx and Gensco's Rizatriptan for Acute Migraine Treatment
• DEA Rules Fenfluramine No Longer a Controlled Substance
• Atogepant’s Indication Expanded to Include Prevention of Chronic Migraine
• FDA Grants Breakthrough Device Designation to Reach Neuro’s Chronic Stroke Platform
• FDA Approves CSL Behring's Immune Globulin Subcutaneous Prefilled Syringe for PI and CIDP

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
1. Zivadinov R, Jakimovski D, Burnham A, et al. Comprehensive Assessment of Severely Affected Multiple Sclerosis (CASA-MS) Study. Presented at: ACTRIMS Forum; February 25-28, 2023; San Diego, CA. P430. www.abstractsonline.com/pp8/#!/10822/presentation/468

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine. 

Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics
• 3:00 – Understanding drug-to-drug interactions for PDP
• 5:05 – Decision making with quetiapine and negative cognitive effects
• 7:10 – Improved use of pimavanserin since approval
• 9:00 – Neurology News Minute
• 11:40 – Potential predictors of mortality in Parkinson disease psychosis
• 15:20 – Possibility of preventing PD psychosis
• 17:20 – Future research on identifying subgroups of responders to treatment

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis
• Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia
• Eplontersen Continues to Show Clinical Benefit in Long-Term Analysis of hATTR Polyneuropathy
• Reldesemtiv to be Discontinued in ALS Following Data Monitoring Committee Analysis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Eric Zhou, PhD, assistant professor of pediatrics at Harvard Medical School. He spoke on a recently conducted study assessing the link between narcolepsy in adolescents and social relationship health. Specifically, he talked about how the sleep disorder impacts mood, physical activities, driving, and other long-term health outcomes, as well as ways we can help adolescents with narcolepsy at the earliest stages. 

Looking for more narcolepsy discussion? Check out the NeurologyLive® narcolepsy clinical focus page.

Episode Breakdown:

• 1:20 – Identified links between narcolepsy and social relationships
• 3:05 – Long-term impacts of affected mood, physical activities, and driving 
• 4:15 – Current assessment of narcolepsy in adolescents
• 5:30 – Neurology News Minute
• 8:05 – Attempts to prevent narcolepsy at earliest stages
• 9:15 – Implementing programs in school to help adolescents with narcolepsy
• 11:20 – Future research on narcolepsy in younger populations

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA to Hold AdComm Meeting for Investigational DMD Treatment SRP-9001
• Treg Suppressing Agent COYA 302 Shows Slowing of ALS Disease Progression
• FDA Issues Complete Response Letter for AbbVie’s 24-Hour Continuous Carbidopa/Levodopa Pump
• FDA AdComm Panel Supports Neurofilament Light as Surrogate Biomarker for Tofersen, With Questions Regarding Clinical Benefit

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of trofinetide (Daybue; Acadia) in Rett syndrome. Offering commentary is Jeffrey L. Neul, MD, PhD, the Annette Schaffer Eskind Chair and director of the Vanderbilt Kennedy Center, and professor of pediatrics at Vanderbilt University Medical Center, and the lead investigator on the phase 3 study of the drug, called LAVENDER (NCT04181723). Trofinetide is a synthetic analog of the amino‐terminal tripeptide of IGF-1, and is now the first treatment approval for Rett syndrome, marking a milestone in the field of developmental disorder care.

For more of NeurologyLive®'s coverage of trofinetide's approval, head here: FDA Approves Acadia's Trofinetide for Rett Syndrome
Episode Breakdown:

• 0:30 – Trofinetide (Daybue; Acadia) approved for Rett syndrome
• 1:30 – Jeffrey L. Neul, MD, PhD, on the approval
• 4:10 – Prevalence of Rett syndrome and the impact on research
• 5:40 – Supporting data from the phase 3 LAVENDER study
• 7:20 – Safety data from the clinical development and managment of common adverse events
• 8:45 – Closing thoughts

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older News Release. Acadia Pharmaceuticals. March 10, 2023. Accessed March 13, 2023. https://acadia.com/media/news-releases/acadia-pharmaceuticals-announces-u-s-fda-approval-of-daybue-trofinetide-for-the-treatment-of-rett-syndrome-in-adult-and-pediatric-patients-two-years-of-age-and-older/
2. Neul JL. Rett Syndrome. National Organization for Rare Diseases. Updated December 17, 2019. Accessed March 13, 2023. https://rarediseases.org/rare-diseases/rett-syndrome/

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Elizabeth “Eli” Pollard, vice president & chief education and training officer at the Parkinson's Foundation, and the executive director of the World Parkinson Coalition. She spoke about the foundation's ongoing efforts in providing education about Parkison disease (PD), the challenges of managing a growing population of patients, the need for community physicians and specialists to work in unison, and more.

>>Click here to access the Parkinson Foundation's educational series.

Looking for more Parkinson disease discussion? Check out the NeurologyLive® PD disease spotlight page.

Episode Breakdown:

• 1:20 – The need for education across the PD care paradigm
• 4:40 – An overview of the 6-part educational series 
• 6:10 – The inclusion of specialties such as dentistry in the care of PD
• 9:40 – Using training to overcome gaps in multidisciplinary care
• 13:05 – Challenges in educating a large population of providers
• 16:55 – Neurology News Minute
• 19:00 – Improving access to clinical education
• 24:07 – The Foundation’s goal to inspire learning to improve care
• 26:30 – Closing thoughts

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Theranica's Nerivio for Preventive Treatment of Migraine
• FDA Approves Omaveloxolone As First Treatment for Friedreich Ataxia
• FDA Accepts Supplemental BLA for Traditional Approval of Lecanemab
• FDA Clears Abbott’s Alinity i Lab-Based Blood Test for Traumatic Brain Injury

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Darin Okuda, MD, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more. 

Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.

Episode Breakdown:

• 1:20 – Overview of ARISE and conduct of study
• 4:20 – Potential subgroup responders to dimethyl fumarate
• 8:10 – Efforts to improve the detection of radiologically isolated syndrome
• 10:05 – Neurology News Minute
• 11:55 – Next steps of research following ARISE
• 16:50 – Closing thoughts on significance of the study

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter
• Aducanumab’s Label Updated to Include Risks on Brain Bleeding
• Primary Care Physicians Show Greater Confidence in Diagnosing Alzheimer Disease Through DISCERN Skin Test
• FDA Approves Extended-Release Deutetrabenazine for Huntington Disease Chorea, Tardive Dyskinesia

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome. Ann Neurol. 2023;93(3):604-614. doi:10.1002/ana.26555

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai. She spoke about research she and colleagues recently presented at the American Epilepsy Society Annual Meeting on poststroke epilepsy, the ongoing clinical efforts to manage seizures occurring after stroke, what studies still need to explore, and more.

Looking for more epilepsy discussion? Check out the NeurologyLive® epilepsy clinical focus page. Or, for more stroke-focused content, check out our stroke clinical focus page.

Episode Breakdown:

• 1:20 – Background on the multicenter study
• 3:30 – Goals of the study and main findings
• 5:25 – Surprising findings from the study
• 6:50 – The understanding of this association in clinical care
• 9:25 – Neurology News Minute
• 11:55 – Current state of prognostication post stroke
• 16:50 – The lack of standardized approach to monitoring
• 20:50 – Lingering needs for future studies
• 22:55 – Closing thoughts

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts New Drug Application for Duchenne Therapy Vamorolone
• Enrollment for Pivotal Phase 3 PHOENIX Study of AMX0035 Completed
• Alzheimer’s Association Panel Offers Considerations for New Definition of Meaningful Change in Drug Trials
• Sanofi Discontinues Phase 3 Study of Tolebrutinib in Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Atuesta FC. Seizures After Ischemic Stroke: A Matched Multicenter Study. Presented at: AES Annual Meeting; December 2-6, 2022; Nashville, TN, and virtual. SIG.
2. Ferreira-Atuesta C, Döhler N, Erdélyi-Canavese B, et al. Seizures after Ischemic Stroke: A Matched Multicenter Study. Ann Neurol. 2021;90(5):808-820. doi:10.1002/ana.26212

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease (PD), some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page, or for more PD-focused content, check out our disease spotlight on Parkinson disease.

Episode Breakdown:

• 1:20 – Lingering unmet needs in Parkinson disease management
• 3:10 – The advances in identifying therapeutic targets in PD
• 4:25 – Bridging the gap to more effective long-term treatment
• 6:00 – Overview of IPX203 and its potential to treat PD
• 7:45 – Neurology News Minute
• 10:15 – Possible advantages of IPX203
• 13:25 – Safety profile of IPX203 in clinical development
• 15:50 – The importance of addressing dose-wearing off
• 16:40 – Closing thoughts

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Neurelis Files IND for Potential First Therapy to Treat Cerebral Cavernous Malformations
• CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine
• FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data
• FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845
• Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Sarah Boyce, president and CEO of Avidity Biosciences, who shared insight into the company's ongoing work with its antibody oligonucleotide conjugates (AOC) platform and the focus on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) treatments, as well as the challenges with developing successful RNA therapies, and more.

Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® neuromuscular clinical focus page: neurologylive.com/clinical/neuromuscular

Episode Breakdown:

• 1:20 – Current limitations with RNA therapies
• 4:50 – The decision to focus on rare genetic muscle diseases
• 7:45 – The patient needs in DM1, FSHD, and DMD
• 9:05 – Neurology News Minute
• 12:25 – Other clinical areas of focus and collaboration for Avidity
• 14:10 – Upcoming data presentations planned for 2023 in DMD and myotonic dystrophy
• 16:15 – The benefits of collaboration in the rare disease community
• 18:15 – Looking ahead to the future of therapies in rare muscular disease

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Anti-CD20 Therapy Ublituximab Gains FDA Approval for Relapsing Multiple Sclerosis
• FDA Clears First Stroke-Specific Radial Access Platform for Mechanical Thrombectomy
• FDA Designates Myasthenia Gravis Agent Rozanolixizumab Application for Priority Review
• FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease
• FDA Accepts sBLA for Revance’s Cervical Dystonia Treatment DaxibotulinumtoxinA

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, "Key Challenges Facing Neurology in the Year Ahead," Natalia Rost, MD, President of the American Academy of Neurology (AAN), Stroke Division Chief at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School, joins NeurologyLive to discuss the top clinical priorities shaping neurology in 2026.

Throughout the discussion, Rost outlines the most urgent unmet needs across neurology, including expanding equitable access to care, integrating preventive neurology into routine practice, strengthening the workforce, and closing persistent evidence gaps. She explains how the AAN Brain Health Initiative provides a practical framework for embedding brain health into everyday clinical encounters. The conversation also explores the growing role of biomarkers, imaging, and digital tools in care delivery, where innovation may be outpacing evidence, and how the Academy aims to guide ethical and evidence based implementation while addressing ongoing health equity gaps.

Episode Breakdown:

• 1:10 – Most urgent unmet clinical needs facing neurology in 2026
• 3:25 – Implementing brain health in everyday clinical practice
• 8:00 – Role of biomarkers, imaging, and digital tools in routine neurologic care
• 11:20 – AAN priorities for education, advocacy, and clinical guidance in 2026
• 14:25 – Major clinical gaps driving health inequities in neurologic care and outcomes

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of lecanemab (Leqembi; Eisai) in Alzheimer disease. Offering commentary is Sharon Cohen, MD, FRCPC, a behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of the antiamyloid agent. Lecanemab was approved via the accelerated approval pathway, with the application supported by data from the phase 2b proof-of-concept clinical trial, known as Study 201 (NCT01767311). The pivotal phase 3 Clarity AD trial (NCT03887455) is anticipated to serve as supplementary data and is pending review by the FDA.

For more of NeurologyLive®'s coverage of lecanemab's approval, head here: FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease
For more coverage of Alzheimer disease and dementia, head to NeurologyLive®'s Alzheimer & Dementia clinical focus page.

Episode Breakdown:

• 0:30 – Lecanemab (Leqembi; Eisai) approved for Alzheimer disease
• 1:35 – Sharon Cohen, MD, FRCPC, on the approval
• 3:15 – Supporting context on the accelerated approval pathway for lecanemab
• 4:50 – Questions about access amid current CMS guidance
• 6:25 – Data from the supporting phase 2 study, Study 201
• 7:15 – Safety and the 3 patient deaths reported in the clinical trial program

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. FDA grants accelerated approval for Alzheimer's disease treatment. FDA. News release. January 6, 2023. Accessed January 9, 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more.

Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023. In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group.

Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia/Alzheimer clinical focus page: neurologylive.com/clinical/dementia-alzheimer

Episode Breakdown:

• 1:20 – Lecanemab's safety profile from Clarity AD
• 4:15 – Amyloid-related imaging abnormalities and lecanemab use
• 6:40 – The landscape of Alzheimer disease therapeutics
• 8:10 – Neurology News Minute
• 10:15 – What research has revealed about treatment approaches
• 13:00 – How clinical trials have evolved in dementia research
• 14:40 – The possibility of induction therapy in Alzheimer disease
• 16:30 – Looking ahead to the next steps in treatment development
• 18:00 – Progress toward treating Alzheimer disease earlier

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!
Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays
• BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment
• Seizure-Free Days and Duration Intervals Increased with Fenfluramine in Dravet Syndrome

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics.

Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus page: neurologylive.com/clinical/movement-disorders

Episode Breakdown:

• 1:20 – An overview of the state of virtual reality in medicine
• 2:20 – The Cleveland Clinic Virtual Reality Shopping platform
• 6:45 – The importance of mimicking the details of reality
• 8:05 – Misconceptions and surprises with VR for Parkinson disease
• 11:45 – Neurology News Minute
• 15:05 – How VR can be used in prodromal Parkinson disease 
• 19:00 – Biomarkers for Parkinson disease
• 21:15 – Using VR as a targeted therapy
• 23:20 – The opportunity in medicine with VR systems

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype
• Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
• Duchenne Gene Therapy SRP-9001 Wins Priority Review
• Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses
• Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with George Small, MD, an adult neurologist at Allegheny Health Network, who discussed the state of care for myasthenia gravis and its recent success, the corresponding changes to patient care, and the current era of treatment that the field has entered, among other topics.

Looking for more myasthenia gravis discussion? Check out this NeurologyLive® Peers & Perspectives series, featuring James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN: Updates in the Management of Myasthenia Gravis Peers and Perspectives

Episode Breakdown:

• 1:15 – The perspective on the current state of care in myasthenia gravis
• 4:05 – The rapidly evolving treatment landscape
• 6:40 – Allegheny Health Network's approach to myasthenia gravis care
• 10:05 – Treatment selection among patient groups
• 15:45 – Neurology News Minute
• 18:45 – Current challenges and adjustments with treatments
• 21:20 – Nonpharmacologic approaches to myasthenia gravis
• 26:55 – Challenges for patients and education around treatment access
• 28:35 – The future of myasthenia gravis care

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Neurosteer Single-Channel EEG Platform Cleared by FDA
• Neurocrine Biosciences Submits Supplemental NDA for Valbenazine in the Treatment of Huntington Disease Chorea
• FDA Refuses to File BrainStorm’s BLA for NurOwn Mesenchymal ALS Therapy
• FDA Accepts NDA for Parkinson Disease Treatment IPX203
• FDA Accepts NDA for Myasthenia Gravis Treatment Zilucoplan

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a number of experts in the clinical care of MS who were in attendance at the 2022 ECTRIMS Congress, including Darin T. Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center; Federica Picariello, PhD, a health psychologist and postgraduate research associate at King's College London; Brenda Banwell, MD, chief of the Division of Neurology and codirector of the Neuroscience Center at the Children's Hospital of Philadelphia; Riley Bove, MD, associate professor of neurology, University of California, San Francisco; Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research Unit at the University of Melbourne, and head of the MS Centre at the Royal Melbourne Hospital; and Marisa McGinley, DO, a neurologist at the Mellen Center for MS at Cleveland Clinic.

Click here for more coverage of ECTRIMS 2022.

Episode Breakdown:

• 1:15 – Darin Okuda, MD, on the implications of the ARISE data in RIS
• 5:50 – Federica Picariello, PhD, on addressing fatigue and its mechanisms
• 10:40 – Brenda Banwell, MD, on advances in pediatric-onset MS
• 16:05 – Riley Bove, MD, on treatment NMOSD in pregnancy and post partum
• 21:30 – Tomas Kalincik, MD, PhD, on stem cell transplantation in MS
• 27:00 – Marisa McGinley, DO, on the optimal experience of teleneurology

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with the chairs of the recently hosted International Congress on the Future of Neurology (IFN), including Stephen Krieger, MD, professor of neurology and neurologist at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai; Richard Isaacson, MD, director of the Center for Brain Health at the Florida Atlantic University Schmidt College of Medicine; and Jessica Ailani, MD, associate professor of neurology and director of the MedStar Georgetown Headache Center. They joined the show to recap their experience at the 2022 IFN meeting, discuss the value of cross-specialty interactions, share their perspective on the future of their fields, and more.

To learn more about the Congress and other Physician's Education Resource CME activities, visit gotoper.com.

Episode Breakdown:

• 1:15 – Richard Isaacson, MD, on his experience
• 3:20 – Stephen Krieger, MD, on his experience
• 6:20 – Jessica Ailani, MD, on her experience
• 9:45 – Krieger on the benefits of cross-specialty interactions
• 11:25 – Isaacson on the concept of earlier identification of disease
• 14:25 – Ailani on increasing diversity and discussion across neurology
• 16:00 – Krieger on the takeaways from COVID-19 in multiple sclerosis
• 18:55 – Ailani on the challenges of comorbidity and telemedicine
• 20:55 – Isaacson on the need to focus on the future of neurology

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Yuri Maricich, MD, MBA, internal medicine physician, and chief medical officer and head of development, Pear Therapeutics. He joined the show to discuss the current use of digital therapeutics in insomnia such as cognitive behavioral therapy, the state of education and treatment for the sleep disorder, some of the challenges in care, and more.

Episode Breakdown:

• 1:15 – The positives of digital therapeutics in insomnia care
• 3:50 – Overview of a recent study from Maricich and colleagues
• 8:40 – Prioritization of sleep in clinical care
• 11:20 – Lack of clinical use of prescription digital therapeutics
• 13:05 – Neurology News Minute
• 15:30 – Differences for CBT-I among treatment-naïve individuals
• 18:05 – Use of CBT-I as a supplementary treatment tool
• 20:10 – Research needs and ongoing efforts
• 23:15 – What clinicians need to know about CBT-I and digital therapeutics
• 25:50 – Closing thoughts

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Alzheimer Disease Agent Lecanemab Shows Reduction in CDR-Sum of Boxes in Clarity AD
• Verdiperstat Fails to Differentiate From Placebo in Critical HEALEY ALS Platform Trial
• AMX0035 Approved for the Treatment of ALS
• CNM-Au8 Shows Survival Benefit in HEALEY ALS Trial, But Fails to Meet End Points

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Forma F, Knight TG, Thorndike FP, et al. Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia. Clinicoecon Outcomes Res. 2022;14:537-546. doi:10.2147/CEOR.S368780

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Ambereen Mehta, MD, MPH, palliative care physician, and assistant professor of medicine, Johns Hopkins Bayview Medical Center. She joined the show to discuss palliative care and its evolving role in the care paradigm for patients with chronic neurologic disease, as well as its history in the United States, how it differs from hospice care, and more.

To learn more about neuropalliative care, head to our International Neuropalliative Care Society (INPCS) partner page, or click here to learn more about the INPCS 2022 Annual Meeting.

Episode Breakdown:

• 1:15 – Overview of palliative care and its purpose
• 5:40 – Differences between hospice and palliative care
• 7:55 – History of palliative care in the United States
• 12:25 – Palliative care's fit in neurologic care
• 15:10 – Neurology News Minute
• 17:10 – Benefits of care for caregivers
• 21:15 – Palliative care resources and societies
• 22:30 – Neuropalliative care and its current goals
• 26:30 – Benefits for clinicians of implementing neuropalliative care
• 30:20 – Recommendations for physicians
• 36:00 – Tips for trying palliative care practices and findings resources

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Accepts Application for Trofinetide in Rett Syndrome
• LIFT-AD Study Amended to Assess Alzheimer Disease Agent Fosgonimeton as Monotherapy
• Tolerizing MS Vaccine Displays Efficacy in Model of Relapsing-Remitting Multiple Sclerosis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Shemme AJ, Phillips JN, Bloise R, Koehler TJ, Gorelick PB, Francis BA. The Impact of a Neurocritical Care and Neuropalliative Collaboration on Intensive Care Unit Outcomes. Am J Hosp Palliat Care. 2022;39(6):687-694. doi:10.1177/10499091211060055
2. Mehta AK, Wright SM, Wu DS, Harris CM. Palliative Care Involvement in Patients Hospitalized in the United States with Aneurysmal Subarachnoid Hemorrhage. J Palliat Med. 2021;24(10):1555-1560. doi:10.1089/jpm.2021.0116
3. Williamson TL, Adil SM, Shalita C, et al. Palliative Care Consultations in Patients with Severe Traumatic Brain Injury: Who Receives Palliative Care Consultations and What Does that Mean for Utilization? Neurocrit Care. 2022;36(3):781-790. doi:10.1007/s12028-021-01366-2
4. Bužgová R, Kozáková R, Bar M. The effect of neuropalliative care on quality of life and satisfaction with quality of care in patients with progressive neurological disease and their family caregivers: an interventional control study. BMC Palliat Care. 2020;19(1):143. doi:10.1186/s12904-020-00651-9
5. Mehta AK, Jackson NJ, Wiedau-Pazos M. Palliative Care Consults in an Inpatient Setting for Patients With Amyotrophic Lateral Sclerosis. Am J Hosp Palliat Care. 2021;38(9):1091-1098. doi:10.1177/1049909120969959
6. Lou W, Granstein JH, Wabl R, Singh A, Wahlster S, Creutzfeldt CJ. Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury. Neurocrit Care. 2022;36(2):504-510. doi:10.1007/s12028-021-01335-9.
7. Miyasaki JM, Kluger BM (ed). Handbook of Clinical Neurology. Neuropalliative Care - Part I. 2022;190:2-243
8. Lou W, Granstein JH, Wabl R, Singh A, Wahlster S, Creutzfeldt CJ. Taking a Chance to Recover: Families Look Back on the Decision to Pursue Tracheostomy After Severe Acute Brain Injury. Neurocrit Care. 2022;36(2):504-510. doi:10.1007/s12028-021-01335-9
9. Phillips JN, Besbris J, Foster LA, Kramer NM, Maiser S, Mehta AK. Models of outpatient neuropalliative care for patients with amyotrophic lateral sclerosis. Neurology. 2020;95(17):782-788. doi:10.1212/WNL.0000000000010831

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Christopher Elder, MD, clinical assistant professor of neurology, Comprehensive Epilepsy Center, NYU Langone Health. He joined the show to talk about the latest updates in the care of patients with epilepsy, the clinical therapeutic pipeline developments on the horizon, and the need to continue stressing conversations around sudden unexpected death in epilepsy (SUDEP).

Episode Breakdown:

• 1:15 – The rise of neurostimulation in epilepsy care
• 4:00 – Increasing implantation of minimally invasive options
• 5:15 – Patient reception to nontherapeutic approaches
• 7:45 – The impact of cenobamate (Xcopri; SK Life Science) on the paradigm
• 10:35 – Managing refractory epilepsy
• 12:00 – Upcoming options for those with generalized epilepsy
• 13:50 – Neurology News Minute
• 18:30 – Path forward for gene and cell therapies in epilepsy
• 21:00 – The need to improve early recognition of epilepsy
• 25:20 – Standardizing questionnaires and information for epilepsy
• 27:00 – The need to continue discussing SUDEP

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Midazolam Autoinjector for Status Epilepticus
• Sirolimus Topical Gel Available for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
• FDA Lifts Hold on Phase 2 Trial of SRP-5051 in DMD Amenable to Exon 51 Skipping
• Philips Respironics Recalls Masks for BPAP and CPAP Machines After Safety Concerns
• FDA Advisory Committee Votes to Recommend AMX0035 for Treatment of ALS

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Chris Winter, MD, owner of Charlottesville Neurology and Sleep Medicine clinic and CNSM Consulting, and an author of several books on sleep. he shared his perspective on the state and prevalence of pediatric sleep disorders, how the current system of schooling affects children's sleep, and the trends that are occurring in sleep research and awareness.

Episode Breakdown:

• 1:15 – Current conversations around school start times and sleep
• 5:25 – The role of virtual schooling in helping sleep
• 9:00 – Education about sleep for children, parents, and professionals
• 13:15 – The current trends in sleep-focused behaviors 
• 14:30 – The prevalence and awareness of pediatric sleep disorders
• 16:35 – Neurology News Minute
• 19:30 – Improving sleep evaluation in daily clinical practice
• 24:00 – The trends in sleep medicine
• 26:30 – Leveraging the inherent attractiveness of sleep conversations
• 27:00 – Tips for the clinical community and self-advocacy

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Two Patient Deaths Reported With Zolgensma Administration in SMA
• Passage Bio Doses First Patient in Frontotemporal Dementia Gene Therapy Trial
• BLA Application to Be Submitted for ALS Agent NurOwn Following Phase 3 Statistical Corrections
• Jazz Initiates Trial Assessing Cannabidiol in Epilepsy With Myoclonic-Atonic Seizures

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Amaal Starling, MD, FAHS, FAAN, joins the podcast to provide clinical perspective on the INFUSE real world study evaluating IV eptinezumab in adults with migraine who previously found one or more CGRP preventive options ineffective, based on data presented at the 2026 Headache Cooperative of the Pacific Annual Conference. Starling, an associate professor of neurology at Mayo Clinic College of Medicine and a study author on INFUSE, discusses how clinicians should interpret the magnitude of benefit in a high burden population and why IV delivery, including rapid and consistent bioavailability, may help explain early and sustained response. The conversation also explores what the findings suggest for real world care and treatment sequencing, how migraine trials can better capture patient experience through outcomes like good days and PGIC, and what precision medicine research could look like next as the field pushes toward predictive modeling and individualized treatment selection.

Looking for more Headache & Migraine discussion? Check out the NeurologyLive® Headache & Migraine clinical focus page.

Episode Breakdown:

• 1:20 – Interpreting real world response after prior CGRP preventive failure
• 4:25 – Mechanistic reasons IV eptinezumab may drive early sustained benefit
• 6:25 – Clinical implications for earlier, more robust treatment sequencing
• 8:50 – Neurology News Network 
• 11:20 – Integrating good days and Patient Global Impression scales into migraine trial design
• 15:30 – Future studies needed to advance precision migraine care

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS
• Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies
• Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study of Ocular Myasthenia Gravis

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Olwen C. Murphy, MBBCh, assistant professor of neurology, Johns Hopkins University; and Matthew R. Vogt, MD, PhD, assistant professor of pediatric infectious diseases, University of North Carolina at Chapel Hill. The pair spoke about the current clinical understanding of acute flaccid myelitis (AFM) and the existing treatment approach, as well as the current guidelines and the need to improve awareness ahead of the peak infection months in autumn.

Click here for AFM resources:

• CDC – Acute Flaccid Myelitis
• SRNA – Acute Flaccid Myelitis

Episode Breakdown:

• 1:15 – Background on AFM from the neurology perspective
• 3:50 – Background on AFM from the infectious disease perspective
• 6:10 – Ongoing work and research into AFM cases
• 9:15 – The evolution of the clinical care of patients with AFM
• 13:00 – The diagnostic approach and guidelines for AFM
• 16:05 – Neurology News Minute
• 19:00 – State of care and treatment approaches
• 21:45 – The importance of recognition of AFM
• 26:50 – Testing and differential diagnosis of AFM
• 32:30 – Message for the clinical community around awareness

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Significant Correlations Identified Between Mental Health and Migraine
• FDA Issues Second CRL for Pimavanserin, Now for the Treatment of Alzheimer Disease Psychosis
• ICER Releases Report Comparing Cost-Effectiveness of ALS Agents Oral Edaravone and AMX0035
• FDA Extends Review of Omaveloxolone in Friedreich Ataxia

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Darin T. Okuda, MD, professor of neurology and director of Neuroinnovation and the Multiple Sclerosis & Neuroimmunology Imaging Program at The University of Texas Southwestern Medical Center at Dallas; and Karin Cook, senior vice president of medical strategy and clinical ethnographer, Heartbeat Medical Communications. The pair spoke about their research into the wasted costs associated with disease-modifying therapies (DMTs) for patients with multiple sclerosis, what they've observed at their center, the wide-reaching impact of this waste on the healthcare continuum, and the future solutions that are being worked on for this problem.
Click here for more coverage of this story:

• Multiple Sclerosis DMT Waste Is Staggering, New Study Shows
• Wasted DMTs in Dr. Okuda's office [Image]

Episode Breakdown:

• 1:45 – Background on the study conducted by Okuda et al.
• 4:05 – Perspective on the cost driven by DMT waste 
• 6:30 – Current landscape of prescriptions and adherence in MS
• 8:35 – Disparities in MS treatment adherence
• 11:00 – The link to the physician-patient relationship
• 16:40 – The process of choosing a DMT and shared decision-making 
• 23:00 – Neurology News Minute
• 25:45 – Finding solutions to the DMT waste problem
• 33:40 – The role of the individual neurologist and patient
• 38:30 – Access to specialist care and resources
• 42:40 – Building trust with patients and general medical mistrust
• 47:00 – Next steps and closing thoughts

This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Zonisamide Oral Suspension FDA-Approved for Partial Seizures in Epilepsy
• FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy
• FDA Clears Rapid Hyperdensity Tool for Inclusion in RapidAI Platform for Neurovascular Conditions
• ALS Therapy Tofersen Has NDA Accepted by FDA, Granted Priority Review

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
1. Okuda DT, Burgess KW, Cook K, McCreary M, Winkler MD, Moog TM. Hiding in plain sight: the magnitude of unused disease-modifying therapies in multiple sclerosis and strategies for reducing the economic burden. Mult Scler Relat Disord. 2022;63:103920. doi:10.1016/j.msard.2022.103920

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Rajesh Pahwa, MD, professor of neurology, and director, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center. He spoke about the current state of treatment for essential tremor, including the therapeutic and surgical options for this population, and shared his perspective on the latest advances in clinical care and diagnosis, the role of the patient-physician relationship, and the research into the disease's underlying processes.
Episode Breakdown:

• 1:25 – Overview of the current state of essential tremor care
• 7:05 – Changes in thinking about essential tremor
• 9:05 – Potential in the therapeutics pipeline
• 10:45 – Advances in the understanding of essential tremor
• 12:40 – Neurology News Minute
• 15:30 – The role of shared decision-making in care
• 18:50 – Surgical options for essential tremor treatment
• 22:00 – Education and diagnosis outside of movement specialists
• 24:00 – Advances on the horizon

Check out Medical World News' Second Opinion only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Biogen, Alectos Announce Licensing Agreement for Parkinson Disease GBA2 Inhibitor AL01811
• FDA Advisory Committee Agrees to Reconvene for Decision on ALS Treatment AMX0035
• FDA Accepts BLA for Lecanemab in Alzheimer Disease, Sets PDUFA Date for January 2023
• FDA Places Clinical Hold on Phase 2/3 ReMEDy2 Trial of DM199 in Acute Ischemic Stroke

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Serena L. Orr, MD, MSc, a pediatric neurologist and headache specialist at the University of Calgary and Alberta Children's. She spoke about the recent work she's done looking into mental health conditions among pediatric patients with migraine, as well as how the field has progressed in managing the disease and advocating for these individuals.
Episode Breakdown:

• 1:25 – Overview of systematic review of depressive and anxiety symptoms in pediatric migraine
• 5:30 – Clinical implications of the data and the need for advocacy for this population
• 8:50 – Possible differences between children and adolescents
• 10:15 – Remaining questions for this area of research
• 13:20 – The needs from a research funding perspective
• 15:05 – Neurology News Minute
• 17:20 – Shifting the paradigm of pediatric headache research
• 21:35 – Challenges in awareness despite patient population size
• 24:15 – Exposure to headache medicine education among trainees
• 26:25 – Conducting clinical trials in pediatric migraine

Check out Medical World News' Second Opinion only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Advisory Committee Votes Down Pimavanserin's Efficacy in AD Psychosis Ahead of PDUFA
• Parkinson Disease Symptom Data Tool StrivePD Receives FDA Clearance
• AbbVie Submits Supplemental New Drug Application for Atogepant in Chronic Migraine
• FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns
• FDA Pauses Tolebrutinib Trials in MS, Myasthenia Gravis Over Liver Injuries

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a number of individuals who presented data and spoke at the Consortium of Multiple Sclerosis Centers Annual Meeting, on topics ranging from the examination of longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders, JZP-258’s impact on the treatment of patients with idiopathic hypersomnia, and the understanding of the signs and risks associated with sleep disorders and Alzheimer disease.

This episode is brought to you by Medical World News Second Opinion. Check out new episodes every Tuesday and Thursday only on medicalworldnews.com.

Those featured include (in order of appearance): 

• Afsara Zaheed, graduate student, University of Michigan
• Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, and associate clinical professor, Medical University of South Carolina
• Ruth Benca, MD, PhD, professor and chair, Psychiatry & Human Behavior, Wake Forest School of Medicine

Episode Breakdown:

• 1:30 – Afsara Zaheed on the longitudinal patterns of difficulties initiating sleep, the associations with subsequent memory trajectories, and whether associations differ across non-Hispanic Black and White men and women.
• 6:00 – Richard Bogan, MD, FCCP, FAASM, on two post hoc analyses that explored treatment response for low-sodium oxybate based on the 14-item Idiopathic Hypersomnia Severity Scale and the 8-item, self-reported Epworth Sleepiness Scale.
• 12:05 – Ruth Benca, MD, PhD, on the precursor sleep issues to Alzheimer disease, the differences in sex and race, and the critical need to treat sleep disorders early as possible.

Click here for more coverage of SLEEP 2022.

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. Update Description

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we mark 1 year since the FDA granted accelerated approval to aducanumab (Aduhelm; Biogen), the first approval in Alzheimer disease since 2003. This episode offers an abridged recap of the events that have taken place over the course of its clinical journey, and in the year since that decision. Later this month, the June 2022 issue of NeuologyLive® will include a cover story that features a more in-depth and extensive review of the aducanumab saga and its implications for the clinical community from David S. Knopman, MD, a portion of which is featured in this episode.

The June 2022 issue, including Dr. Knopman's story, can be viewed here: www.neurologylive.com/journals/neurologylive

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

This episode featured the songs "Dreams" and "Stronger" by Alan Špiljak, obtained under the CC BY-NC-ND 4.0 license.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a number of individuals who presented data and spoke at the Consortium of Multiple Sclerosis Centers Annual Meeting, on topics including women with multiple sclerosis, the importance of measuring cognition in MS, the characterization of relapse attacks in neuromyelitis optical spectrum disorder, the use of spinal cord atrophy as a biomarker of disease progression, the potential to save time reviewing complex patient histories, and more.

This episode is brought to you by Medical World News Second Opinion. Check out new episodes every Tuesday and Thursday only on medicalworldnews.com.

Those featured include (in order of appearance): 

• Riley Bove, MD
• Blake E. Dewey, PhD
• Bruce Cree, MD, PhD, MAS
• John DeLuca, PhD
• Shuvro Roy, MD
• Tanuja Chitnis, MD

Episode Breakdown:

• 2:00 – Riley Bove, MD, on the conversations that women with multiple sclerosis have about disease-modifying therapies on social media platforms.
• 5:10 – Blake Dewey, PhD, on the efforts to improve the uptake in the use of spinal cord atrophy as a marker of disease progression.
• 8:45 – Bruce Cree, MD, PhD, MAS, on the latest data from the N-MOmemtum study in neuromyelitis optica spectrum disorder.
• 13:05 – John DeLuca, PhD, on the importance of measuring cognition longitudinally in patients with multiple sclerosis.
• 17:10 – Shuvro Roy, MD, on how the MS Smartform might be able to save physicians time in reviewing complex patient histories.
• 20:30 – Tanuja Chitnis, MD, on the use of foralumab in an older patient with nonactive secondary progressive multiple sclerosis.

Click here for more coverage of CMSC 2022.

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Matthew B. Harms, MD, associate professor of neurology, Columbia University, and medical consultant and care center director, Muscular Dystrophy Association (MDA). He spoke about the progress that the field has seen in recent years in improving the genetic understanding of amyotrophic lateral sclerosis (ALS) and the role that big data can play in care, as well as shared his perspective on the impact that advocacy efforts have had on these advances.
Episode Breakdown:

• 2:05 – Major progress in ALS in recent years
• 4:35 – Key steps forward in genetic testing
• 7:25 – The understanding of genetics in ALS
• 9:20 – The role of databases in the care paradigm
• 11:35 – Neurology News Minute
• 15:25 – Advocacy's role in the last decade
• 18:40 – The state of clinical trials for ALS
• 20:40 – The pipeline of therapies and the future of treatment
• 24:50 – Importance of continued advocacy for ALS

Check out Medical World News' Second Opinion only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• National Institutes of Health Launches Phase 1 Trial to Study Epstein-Barr Virus Vaccine
• Eisai Completes Rolling BLA Submission for Lecanemab to Treat MCI, Alzheimer Disease
• FDA Approves Oral Version of Edaravone for ALS

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Jessica Ailani, MD, director, MedStar Georgetown Headache Center, and associate professor of neurology, MedStar Georgetown University Hospital. She spoke about some recent data in headache medicine that has provided evidence of the in-clinic experience and how the migraine treatment landscape has shifted, and what challenges need to be addressed to achieve the goal of developing personalized treatment regimens for patients.
Episode Breakdown:

• 1:25 – Migraine highlights from the 2022 AAN Annual Meeting.
• 5:00 – Atogepant post hoc analyses showing dose-dependent weight loss.
• 9:25 – Rimegepant data and optimizing available treatments for quality of life.
• 12:50 – Current day-to-day challenges in migraine care.
• 15:10 – Neurology News Minute
• 18:50 – Progress made toward increasing migraine training and education.
• 22:45 – Other specialty's understanding of the migraine population.
• 27:35 – The importance of behavioral interventions in migraine.
• 32:05 – Looking ahead to the future of care.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Axsome Issued CRL for AXS-07 in Acute Migraine Treatment
• FDA Approves Ravulizumab for Adults With Generalized Myasthenia Gravis
• FDA Permits Marketing for Plaque-Detecting Diagnostic Test for Alzheimer Disease

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Yasar Torres-Yaghi, MD, director, Parkinsonism and Dementia Clinic, assistant professor of neurology, MedStar Georgetown University Hosptial, about the current state of therapeutic intervention for movement disorders, and this year's first annual Advanced Therapeutics in Movement & Related Disorders™ Congress, being put on by the PMD Alliance.

Click here to register and find more information on the ATMRD Congress.
Episode Breakdown:

• 3:15 – Background on the new ATMRD Congress.
• 6:20 – Rates of adoption of novel therapeutics for Parkinson disease.
• 9:35 – What attendees should expect from the Congress this year.
• 11:20 – The need for a multidisciplinary approach to movement disorders and the multidisciplinary features of the Congress.
• 12:35 – Neurology News Minute
• 16:30 – Education and understanding about the optimal utilization of advanced therapies in Parkinson disease.
• 19:10 – Ongoing trends and conversations in the movement disorder field.
• 21:30 – Closing thoughts.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves Boston Scientific’s STIMVIEW XT Guided Imaging Software for DBS
• FDA Extends Review of Vutrisiran for ATTR Amyloidosis 3 Months, Now Expected in July 2022
• Higher-dose Erenumab Shows Better Prevention of Progression, Rationale Provided for Initiation at High Dose

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this special Mind Moments episode, Lauren Sansing, MD, MS, FAHA, FANA, Professor of Neurology at Yale School of Medicine, joins the podcast to provide a clinical breakdown of the 2026 International Stroke Conference and its implications for real-world stroke care. Sansing reflects on how this year’s meeting built on prior advances, highlighting expanded global collaboration, greater patient engagement, and a record number of clinical trials presented. The discussion explores which late-breaking studies may influence practice in the coming year, including data on secondary stroke prevention, adjunctive thrombolysis strategies, and evolving patient selection for thrombectomy in extended windows and large core infarcts. Sansing also reviews renewed momentum in neuroprotection research, key updates from the newly released acute ischemic stroke guidelines, emerging pediatric stroke data, and how the conference continues to shape the roadmap for 2027 and beyond.

Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page.

Episode Breakdown:

• 1:00 – Biggest moments and structural evolution of ISC 2026
• 3:15 – Presented practice-changing trial data impacting stroke care
• 7:05 – Thrombectomy strategy and extended window patient selection
• 10:40 – Renewed momentum in neuroprotection research
• 15:20 – Neurology News Network 
• 17:40 – Key updates from the new acute ischemic stroke guidelines
• 25:00 – A brief look-ahead to ISC 2027

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• PTC Withdraws Ataluren Submission as Treatment for Nonsense Mutation Duchenne Muscular Dystrophy
• Microbiome-Targeted Agent PLL001 Passes Safety Check in Phase 1/2 Trial of ALS
• Rimegepant Displays Safety and Efficacy in Study of Adolescents With Migraine

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with a number of individuals who presented data and spoke at the American Academy of Neurology Annual Meeting, on topics ranging from COVID-19's clinical presentation, overall trends in the care of patients with multiple sclerosis, the potential of regenerative medicine in traumatic brain injury, the real-world and long-term use of new therapy for Lennox-Gastaut syndrome, the optimal timing for the newest therapy in neuromyelitis optica spectrum disorder, the Axon Registry and incorporating EHR information into its data collection, and the impact of the pandemic on clinician burnout and mental health.

Note: As part of AAN policy for the Annual Meeting, all individuals were asked to remain masked throughout the week, so there may be some moments of muffled noises as participants adjust or shift their masks.

Those featured include (in order of appearance): 

• Jennifer Frontera, MD
• Stephen Krieger, MD
• Peter McAllister, MD
• Kelly Knupp, MD, MSCS
• Bruce Cree, MD, PhD, MAS
• Shrujal Baxi, MD, MPH
• Indu Subramanian, MD.

Episode Breakdown:

• 1:50 – Jennifer Frontera, MD, on the long-term data collected on COVID-19 post-infection neurological sequelae.
• 9:55 – Stephen Krieger, MD, on the trends in thinking about multiple sclerosis pathogenesis and quality of life.
• 14:05 – Peter McAllister, MD, on the phase 2 STEMTRA trial of stem cell therapy in patients with traumatic brain injury.
• 16:45 – Kelly Knupp, MD, MSCS, on the long-term use of fenfluramine in Lennox-Gastaut syndrome and clinical pearls on titration.
• 19:00 – Bruce Cree, MD, PhD, MAS, on the effect of inebilizumab in patients with neuromyelitis optica spectrum disorder regardless of disease duration.
• 21:05 – Shrujal Baxi, MD, MPH, on the AAN's Axon Registry and how Verana Health is playing a role in data collection.
• 23:55 – Indu Subramanian, MD, on the effects of COVID-19 on physicians and clinicians and the difficulties that have challenged the field.

Click here for more coverage of AAN 2022.

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approvals of ganaxolone (Ztalmy; Marinus Pharmaceuticals) in cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, also known as CDD, as well as fenfluramine (Fintepla; Zogenix/UCB) in Lennox-Gastaut syndrome (LGS). Offering commentary is a pair of experts. The first is Scott Demarest, MD, MSCS, neurologist and clinical director of precision medicine, Children’s Hospital Colorado, and assistant professor of pediatrics-neurology, University of Colorado, and an investigator of the Marigold trial (NCT03572933). The second is Kelly G. Knupp, MD, MSCS, FAES, pediatric neurologist, Children's Hospital Colorado, and associate professor of pediatrics-neurology, University of Colorado, and an investigator of Study 1601 (NCT03355209).

For more of NeurologyLive®'s coverage of ganaxolone's approval, head here: Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder. For more of NeurologyLive®'s coverage of fenfluramine's approval, head here: Fenfluramine FDA-Approved for Treatment of Lennox-Gastaut Syndrome.
For more coverage of epilepsy and seizure disorders, head to NeurologyLive®'s Epilepsy clinical focus page.
Episode Breakdown:

• 0:30 – Ganaxolone (Ztalmy; Marinus) approved for CDD
• 2:30 – Scott Demarest, MD, with his reaction to the approval
• 3:00 – Data from the Marigold study of ganaxolone
• 4:45 – Safety profile of ganaxolone in development
• 5:10 – Demarest on the landscape of care for CDD
• 6:20 – Clinical takeaways ahead of DEA scheduling for ganaxolone
• 8:40 – Fenfluramine (Fintepla; Zogenix/UCB) approved for LGS
• 10:55 – Kelly Knupp, MD, with her reaction to the new indication
• 11:30 – Efficacy data on fenfluramine in LGS
• 13:50 – Safety profile in LGS and Dravet syndrome
• 16:05 – Knupp on the potential to improve quality of life and optimal use

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. News release. March 18, 2022. Accessed March 21, 2022. https://www.businesswire.com/news/home/20220318005282/en/Marinus-Pharmaceuticals-Announces-FDA-Approval-of-ZTALMY%C2%AE-ganaxolone-for-CDKL5-Deficiency-Disorder
2. FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS). News release. UCB. March 28, 2022. Accessed March 28, 2022. https://finance.yahoo.com/news/fintepla-fenfluramine-oral-solution-now-050000058.html

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Friedmann Paul, MD, head, Clinical Neuroimmunology Research Group, NeuroCure Clinical Research Center, and head, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité–Universitätsmedizin Berlin. He shared his perspective on the state of care in neuromyelitis optica spectrum disorder (NMOSD), the need to raise awareness for symptomatic care and patient challenges, and the potential of novel therapeutic approaches to improve care.

Episode Breakdown:

• 2:00 – State of diagnosis and care for NMOSD and similar disorders
• 6:00 – Role of NMOSD Awareness Month and advocacy efforts
• 8:45 – Current challenges with symptomatic management
• 11:20 – Multidisciplinary communication, coordination, and collaboration
• 13:05 – Neurology News Minute
• 16:45 – The potential of self-tolerization and curing NMOSD
• 19:05 – Nonpharmacologic approaches to care
• 20:40 – The need to improve physician awareness and education
• 22:45 – Advice for communicating the diagnosis to patients
• 24:45 – The need for patient advocacy groups

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Donepezil Transdermal System Wins FDA Approval to Treat Alzheimer Disease Dementia
• Sarepta Details Phase 3 EMBARK Study in DMD
• Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Richard K. Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, and associate clinical professor, Medical University of South Carolina. He spoke to the current prevalence and impact of narcolepsy and offered insight into the link between the sleep disorder and cardiovascular health.

Episode Breakdown:

• 1:40 – Overview of narcolepsy
• 5:00 – Manifestation of narcolepsy and misdiagnosis rates
• 8:35 – Link between cardiovascular health and narcolepsy
• 12:10 – Tips to improve healthier behavioral habits
• 16:10 – Resources for physicians

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Seema Khosla, MD, FCCP, FAASM, medical director, North Dakota Center for Sleep. She shared her insight into the American Academy of Sleep Medicine's ongoing initiative to switch to a fixed standard time year-round, as well as offered her perspective on the current state of care for sleep disorders.

Episode Breakdown:

• 1:30 – AASM's position statement on daylight saving time
• 3:15 – The impact of daylight saving time on circadian rhythm
• 5:30 – Patient education on sleep and daylight saving
• 6:40 – What can be learned from similar attempts to address sleep issues
• 10:00 – Evidence in favor of fixed-standard time
• 11:45 – Neurology News Minute
• 14:50 – The state of sleep in the US
• 19:15 – Physicians' relationship with sleep education
• 23:20 – Importance of World Sleep Day and awareness
• 25:30 – Advice for inquiring about patient sleep

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Roche Announces Phase 3 SKYLINE Trial of Gantenerumab in Alzheimer Disease
• FDA Approves Saluda’s Evoke Spinal Cord Stimulation System for Chronic Intractable Pain
• IND Application Accepted for Phase 2b Trial of NOE-101 in Trigeminal Neuralgia

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Rishi MA, Ahmed O, Perez JHB, et al. Daylight saving time: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2020;16(10):1781-1784. doi:10.5664/jcsm.8780 
2. AASM calls for end of seasonal time changes ahead of “springing forward”. News release. AASM. March 9, 2022. Accessed March 10, 2022. https://aasm.org/aasm-calls-for-end-of-seasonal-time-changes-ahead-of-springing-forward/

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Konstantin Karmazin, MD, clinical neurologist, and chief medical officer, Prime PD. He discussed the virtual wellness studio that was recently launched, its capabilities and goals for the community of patients with Parkinson disease, and its benefits for physicians. 

Episode Breakdown:

• 1:25 – Background on Prime PD
• 5:00 – The digital wellness studio's programs for PD
• 9:20 – Future aims for additional disease states
• 12:00 – Neurology News Minute
• 14:20 – Potential to incorporate advanced practice clinicians and specialists
• 17:15 – Feedback from patients and physicians
• 22:30 – How physicians can get involved and/or utilize Prime PD

To learn more about Prime PD, check out their website: www.primepd.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• High-Dose ACI-35.030 Shows Positive Phase 1b/2a Interim Data as Alzheimer Vaccine
• Acadia Resubmits sNDA for Pimavanserin to Treat Alzheimer Disease Psychosis
• Tolebrutinib Shows Favorable Long-Term Safety, Efficacy in Relapsing MS Open-Label Extension

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Dhanashri P. Miskin, MD, clinical assistant professor of neurology, Thomas Jefferson University Hospitals. She offered her insight into the role that cognitive impairment plays as a symptom of multiple sclerosis (MS), the current approach to treatment and management for patients, and what challenges remain for the field to address.

Episode Breakdown:

• 1:25 – Background on cognitive symptoms of MS
• 4:25 – Prevalence of cognitive issues for patients
• 6:05 – Current understanding of the driving factors of cognitive issues
• 8:15 – Management practices and approaches to prevention
• 13:20 – Tips on talking to patients about preventive approaches
• 16:30 – Neurology News Minute
• 19:10 – Challenges in helping patients adjust behavioral habits
• 23:20 – Advances in tracking cognitive changes in MS
• 28:00 – Potential role of EBV infection on these processes
• 30:35 – Most glaring need in addressing cognitive issues in MS
• 33:55 – COVID's impact on MS

Want to learn more about EBV and MS? Click here to register for free for an in-depth NeurologyLive®panel discussion including Scott Newsome, DO (moderator); Alberto Ascherio, DPh, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• 1-Week Epworth Sleepiness Scale for Children and Adolescents Validated for Pediatric Narcolepsy
• Baclofen Oral Suspension Approved for Treatment of Spasticity in Multiple Sclerosis
• Phase 2 Study of CY6463 in Alzheimer Disease With Vascular Pathology Initiated

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Bridget A. Bagert, MD, MPH, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of the Epstein-Barr virus (EBV)-targeted agent, ATA188 (Atara Biotherapeutics). She offered her perspective on the recent data from Ascherio et al on the relationship between EBV and multiple sclerosis (MS) that suggest it may be a root cause of the disease, as well as background on the decades of research that have led to this point and the potential of therapies that target EBV and the B cells it infects for patients with MS.

Episode Breakdown:

• 1:25 – Background and historical data on EBV and MS
• 5:15 – The role B cells play in MS and EBV infection
• 10:20 – The current understanding of EBV as a cause of MS
• 14:20 – Neurology News Minute
• 18:05 – Immediate research needs in this area
• 21:00 – The clinical community’s view of this relationship
• 23:45 – ATA188 as an EBV-targeted approach to MS
• 30:00 – Closing thoughts

Want to learn more about EBV and MS? Click here to register for free for an in-depth NeurologyLive®panel discussion including Scott Newsome, DO (moderator); Alberto Ascherio, DPh, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Roche Designing New Phase 2 Trial of Tominersen in Huntington Disease
• Risdiplam Gets Priority Review for Presymptomatic SMA in Babies Under 2 Months
• Diverse Enrollment, Primary End Point Announced for Phase 4 ENVISION Study of Aducanumab

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Bar-Or A, Pender MP, Hodgkinson SJ, et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis. Presented at ECTRIMS Congress; October 13-15, 2021; Poster P638.
2. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. Published online January 13, 2022. doi:10.1126/science.abj8222

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Anne-Maree Kelly, MD, MClinEd, FACEM, senior emergency physician, Western Health; director, Joseph Epstein Centre for Emergency Medicine Research; professorial fellow, the University of Melbourne; and adjunct professor, Australian Centre for Health Law Research, Queensland University of Technology. She shared her clinical experience treating patients with headache and migraine in the emergency department (ED), offering insight into the factors that influence patient outcomes and the vital need for consensus international guidelines for ED migraine care.

Episode Breakdown:

• 1:35 – Topline findings of a study of migraine in the ED
• 4:55 –The current state of guidelines for treatment and imaging 
• 6:50 – Take-home points for emergency physicians
• 10:20 – State of education on headache and migraine in emergency medicine
• 11:40 – Neurology News Minute
• 14:40 – The stakeholders for developing consensus guidelines
• 16:30 – Additional research that is needed
• 19:20 – The role of experience in managing headache disorders in the ED

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• 5-SENSE Score Validated for Seizure-Onset Zone Identification, May Improve Patient Eligibility for Epilepsy Surgery
• FDA Approves Daridorexant for Insomnia Treatment
• CMS Releases Proposed Decision for Aducanumab Coverage in Alzheimer Disease

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
Kelly AM, Kuan WS, Chu KH, et al. Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)–a multinational observational study. Headache. 2021;61(10):1539-1552. doi:10.1111/head.14230

Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this episode, we're covering the recent approval of daridorexant (Quviviq; Idorsia) for the treatment of insomnia. Offering commentary is Thomas Roth, PhD, director, Sleep Disorders and Research Center, Henry Ford Hospital; professor of psychiatry, Wayne State University School of Medicine; and clinical professor of psychiatry, University of Michigan College of Medicine; and an investigator in the clinical development studies.

For more of NeurologyLive®'s coverage of daridorexant's approval, head here: FDA Approves Daridorexant for Insomnia Treatment.

For more coverage of sleep disorders, head to NeurologyLive®'s Sleep Medicine clinical focus page.
Episode Breakdown:

• 0:30 – Daridorexant (Quviviq; Idorsia) approved for insomnia
• 2:20 – Thomas Roth, PhD, with the clinical takeaways
• 4:30 – Efficacy data from Study 1 and Study 2
• 6:10 – Thomas Roth, PhD, on the efficacy profile
• 8:20 – Safety data from Study 1 and Study 2
• 9:00 – Thomas Roth, PhD, on the safety profile

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCE
Idorsia receives US FDA approval of Quviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed January 10, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Jeff Chamberlain, PhD, joins the podcast during Duchenne Muscular Dystrophy Awareness Week to provide clinical and translational perspective on the evolving landscape of DMD biology and therapy. Chamberlain, professor at the University of Washington School of Medicine and Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center in Seattle, reflects on aspects of Duchenne pathophysiology that may still be underappreciated, including evidence that disease processes begin earlier than once recognized and the growing importance of immunologic factors in shaping progression and therapeutic response. The conversation also explores how neuromuscular specialists should approach treatment timing and combination strategies as gene-targeted therapies expand, the evolving interpretation and limitations of biomarkers such as creatine kinase and dystrophin expression, and what emerging gene therapy platforms may signal for care heading into 2026 and beyond.

Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.

Episode Breakdown:

• 1:15 – Underrecognized aspects of DMD pathophysiology, including early onset and immunologic drivers
• 4:50 – Treatment timing, sequencing, and the rationale for combination strategies
• 8:00 – Neurology News Minute
• 10:30 – Clinical trial and real-world implications of dystrophin and CK as biomarkers
• 16:20 – Anticipated gene therapy innovation and safety considerations heading into 2026

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL
• FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review
• FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Jennifer Majersik, MD, MS, chief, division of vascular neurology, and professor of neurology, University of Utah, who along with 9 other colleagues, authored a report from the American Academy of Neurology (AAN) 2019 Transforming Leaders Program on the ongoing shortage of physicians in neurology. She offered her perspective on the challenge and how it can be addressed from an individual and institutional level.

Episode Breakdown:

• 3:40 – Overview of the shortage in neurology
• 5:00 – Attracting new medical students to neurology
• 7:05 – The role of AAN and medical organizations
• 9:35 – The role of the individual neurologist
• 11:50 – The increase in fellowship training in neurology
• 14:00 – The impact on patient care

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

REFERENCES
1. Majersik JJ, Ahmed A, Chen IA, et al. A shortage of neurologists – we must act now: A report from the AAN 2019 transforming leaders program. Neurology. Published online April 30, 2021. doi:10.1212/WNL.0000000000012111
2. AAMC Report Reinforces Mounting Physician Shortage. News release. AAMC. June 11, 2021. Accessed December 30, 2021. https://www.aamc.org/news-insights/press-releases/aamc-report-reinforces-mounting-physician-shortage

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program (AD-CARE); William B. and Sheila Konar Professor of Psychiatry, School of Medicine and Dentistry, University of Rochester. He shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold.

Episode Breakdown:

• 1:15 – Agents in late-stage development in Alzheimer disease
• 10:30 – Additional agents with promise in the pipeline
• 17:00 – Neurology News Minute
• 21:05 – The next big step forward in Alzheimer
• 31:10 – Learning from prior failures, improving diagnostics
• 45:00 – Looking back on the progress in 2021, and ahead to 2022

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• American Academy of Sleep Medicine Publishes Updated Recommendations on Referring OSA Candidates for Surgery
• Phase 3 Study of BXCL501 for Agitation in Alzheimer Disease Initiated
• FDA Accepts Ublituximab Biologics License Application for Relapsing MS

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, we spoke with Christina Szperka, MD, MSCE, assistant professor of neurology, and director, Pediatric Headache Program, Children's Hospital of Pennsylvania. She offered up her thoughts on the current state of clinical care and awareness of pediatric migraine and shared her insight into the changes the landscape of treatment has undergone.

Episode Breakdown:

• 1:15 – The landscape of pediatric migraine
• 3:00 – Challenges in diagnosing pediatric migraine
• 5:00 – Parental and patient awareness of signs and symptoms
• 6:25 – Differences between adult and pediatric migraine
• 11:35 – Impact of new therapies for pediatric patients
• 15:00 – Neurology News Minute
• 17:35 – The day-to-day clinical care of pediatric migraine
• 20:40 – Medication adherence among children and teens with migraine
• 24:00 – Transitioning patients from pediatric to adult care
• 27:40 – Challenges in conducting pediatric migraine studies
• 30:40 – Biggest advances in the past year and amid COVID-19

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease
• Enrollment Complete for Phase 2 Study of ATH-1017 in Moderate Alzheimer
• FDA Accepts sNDA, Grants Priority Review to Fenfluramine for Lennox-Gastaut Syndrome

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.